Filtered By:
Condition: Bleeding
Cancer: Colorectal Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Inflammation May Be the Culprit Behind Our Deadliest Diseases
In the early days of my medical residency, I met a man whom we’ll call Jason. He arrived to our emergency room on a holiday, nonchalant yet amiable, and complained of mild chest pain. Jason was tall and trim, with a strong South Boston accent and fingertips still faintly stained from his last home-improvement project. He was only 45 years old, but he looked much younger. He didn’t smoke, barely drank alcohol, and his cholesterol levels had always been normal. No one in his family had a history of heart disease. He asked us if we could work quickly—he wanted to be home for dinner with his daughters. [time-...
Source: TIME: Health - April 11, 2023 Category: Consumer Health News Authors: Shilpa Ravella Tags: Uncategorized freelance health Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. Task Force Reconsiders Daily Low-Dose Aspirin Use for Preventing Heart Attacks in Adults Over 60
Older adults without heart disease shouldn’t take daily low-dose aspirin to prevent a first heart attack or stroke, an influential health guidelines group said in preliminary updated advice released Tuesday. Bleeding risks for adults in their 60s and up who haven’t had a heart attack or stroke outweigh any potential benefits from aspirin, the U.S. Preventive Services Task Force said in its draft guidance. For the first time, the panel said there may be a small benefit for adults in their 40s who have no bleeding risks. For those in their 50s, the panel softened advice and said evidence of benefit is less clear....
Source: TIME: Health - October 12, 2021 Category: Consumer Health News Authors: Lindsey Taylor/AP Tags: Uncategorized healthscienceclimate Research wire Source Type: news

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - August 19, 2021 Category: International Medicine & Public Health Source Type: research

Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States.
CONCLUSION: Among those undergoing CABG, the prevalence of comorbid cancer has steadily increased. Outside of major bleeding, these patients appear to share similar outcomes to those without cancer indicating that CABG utilization should be not be declined in cancer patients when otherwise indicated. Further research into the factors underlying the decision to pursue CABG in specific cancer sub-groups is needed. PMID: 32861331 [PubMed - in process]
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Guha A, Dey AK, Kalra A, Gumina R, Lustberg M, Lavie CJ, Sabik JF, Addison D Tags: Mayo Clin Proc Source Type: research

Use of Machine Learning for Prediction of Patient Risk of Postoperative Complications After Liver, Pancreatic, and Colorectal Surgery
ConclusionMachine learning was used to develop an algorithm that accurately predicted patient risk of developing complications following liver, pancreatic, or colorectal surgery. The algorithm had very  good predictive ability to predict specific complications and demonstrated superiority over other established methods.
Source: Journal of Gastrointestinal Surgery - August 4, 2019 Category: Surgery Source Type: research

Sex Difference of Radiation Response in Occupational and Accidental Exposure
Conclusion and Outlook This review summarizes the data from major human studies on the health risks of radiation exposure and shows that sex can potentially influence the prolonged response to radiation exposure (Figure 1 and Tables 1, 2). These data suggest that long-term radiosensitivity in females is higher than that in males who receive a comparable dose of radiation. Our analysis of the literature agrees with the conclusions of the recent report on the Biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences (NAS), United States (National Research Council, 2006). The B...
Source: Frontiers in Genetics - May 2, 2019 Category: Genetics & Stem Cells Source Type: research

Should You Take Aspirin Every Day? Here ’s What the Science Says
Aspirin is best known as an over-the-counter painkiller. But acetylsalicylic acid, as it’s called chemically, has many other health benefits, as well as side effects, in the body that have only become clear in recent years. Here’s what the latest science says about the health benefits and side effects of aspirin, as well as which conditions it may treat and those it doesn’t appear to improve. (If you are taking aspirin for any reason other than for periodic pain relief, it’s best to consult with your doctor to confirm whether the benefits outweigh the risks in your particular case.) How aspirin affe...
Source: TIME: Health - November 8, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthytime Source Type: news

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Conclusion: In ROCKET AF, a history of cancer was associated with a higher risk of bleeding and non-cardiovascular death, but not ischemic events. The relative efficacy and safety of rivaroxaban compared with warfarin were not significantly different in patients with and without a history of cancer. The results of this study are exploratory and should be taken in context of the study population, which may not be generalizable to those with advanced malignancy. Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. PMID: 30219887 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C Tags: Eur Heart J Qual Care Clin Outcomes Source Type: research

Abstract 14: The Influence of Provider Specialty on Anticoagulation Prescription Fills and Stroke Risk in Atrial Fibrillation Patients With History of Cancer Session Title: Poster Session Reception: Young Investigator Award Semi-Finalists
Conclusion: AF patients with cancer were less likely to see a cardiologist, and less likely to fill an anticoagulant prescription than AF patients without cancer. However, cardiology involvement was associated with increased anticoagulant prescription fills and reduced risk of stroke, suggesting a beneficial role for cardiology providers to improve outcomes in AF patients with history of cancer.
Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: ONeal, W. T., Claxton, J., MacLehose, R., Chen, L., Bengtson, L. G., Chamberlain, A. M., Norby, F., Lutsey, P., Alonso, A. Tags: Session Title: Poster Session Reception: Young Investigator Award Semi-Finalists Source Type: research

Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2017 Dec 05;167(11):786-793 Authors: Burns RB, Graham K, Sawhney MS, Reynolds EE Abstract Aspirin exerts antiplatelet effects through irreversible inhibition of cyclooxygenase-1, whereas its anticancer effects may be due to inhibition of cyclooxygenase-2 and other pathways. In 2009, the U.S. Preventive Services Task Force endorsed aspirin for primary prevention of cardiovascular disease. However, aspirin's role in cancer prevention is still emerging, and no groups currently recommend its use for this purpose. To help physicians bala...
Source: Annals of Internal Medicine - December 5, 2017 Category: Internal Medicine Authors: Burns RB, Graham K, Sawhney MS, Reynolds EE Tags: Ann Intern Med Source Type: research

Aspirin for Primary Prevention.
Abstract Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable unce...
Source: Clinical Colorectal Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Richman IB, Owens DK Tags: Med Clin North Am Source Type: research

Aspirin for Primary Prevention
Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable uncertainty about whet...
Source: Medical Clinics of North America - June 1, 2017 Category: Primary Care Authors: Ilana B. Richman, Douglas K. Owens Source Type: research